they can't afford to, they are looking for a partner...any more bright questions? Actually they might still do a smallish Phase II to improve the terms of any potential partnership. I'm sure they have some partners knocking on the door now, but they lack proof for a really large deal, which can be structured with milestones based on progress. The main thing is to keep this drug moving forward ASAP and not sign on with any weak partners.
yes, it could be a big problem for them since the trials and small and rapid. I think they may have underestimated FD.
MEMP is greatly under performing the USO in every time frame. In the past 6 months -43% vs -11%. I'm glad they were hedged and did not go to zero like many other MLP's, but with oil rising, it's frustrating to watch the units greatly under perform. The company tells me $60 and $3 are the magic numbers for them. Getting close and so far, the stock is garbage.
small biotechs usually botch the launch and I doubt ACAD will be any different. It's a buy on dips, but I would be careful. Valuation is not cheap and expectations are not low. Also, ARNA/Axovant may have a competing drug coming. IMO not advice.
that's a low hurdle, just about anyone would have been a major upgrade compared to Hixson and JL. Munshi had one success, kind of, I think he was gone when the company was sold. His last venture was a bust. I'll give him a chance. We will know more when he speaks. Is there an annual meeting? Anyone going?
after talking to the company my understanding is that we will have some meaningful clinical data by the end of this year and they are planning for launch some time in 2018. The trials are small and fairly short, so it won't take as long as most drugs for 4471 to go the approval process, assuming it works.
I'm friends with an MD that has hundreds of patients with chronic pain and the government is going to basically force him into early retirement because they are putting a clamp on prescripts for the commonly used pain meds. 371 will be in very high demand if ARNA can get it to a value point and provide early evidence of efficacy and safety.
It's a little early to make any conclusions, but it seems very promising. ALXN has such a bloated stock price, they should be doing more deals for stock.
once the buying dries up, they move it lower. It's really getting annoying!
start with the BOD. They only have a few non-researchers, which is the area they need to cut the most. All hands should be on deck for clinical dev, the rest is a waste of shareholder money.
so you think that people losing their hard-earned money is a funny thing? Then the answer is Evil. Are you really so insecure that you waste all day every day telling people how stupid they were and how smart you were? Give yourself a pat on the back, grow up and move on man. Is this really your life's achievement?
Uneducated with no real job prospects? Evil? Angry? Loser? Nothing better to do? Short? Doing a public service warning unsuspecting shareholders? Trying to buy low? Crazy? Fired/disgruntled? Did I miss anything?
BB's also made a ton in ACHN and SGEN. It's good to have them on board. The larger their stake, the better. Just the opposite with DF bio-short HF loan sharks.
Maybe this has already been posted. Their minions are still hard at work. That last 16MM might be more difficult to cover. Clearly shorts are covering/looking to exit. Good trade for them, but maybe the party is nearing an end (maybe not until 2017) but it will take time. That last 10MM shares might be difficult to cover.
Good catch. Looks like some good institutions added and Deerfield sold out, both positive. I don't like to own DF stocks.